First Tracks Biotherapeutics, Inc.
NASDAQTRAX — First Tracks Biotherapeutics — has shed nearly 9% in a week despite one of the most bullish analyst postures of any small-cap biotech on Nasdaq, making the gap between Street conviction and price action the central tension heading into September. The options market is not reflecting caution. The put/call ratio has collapsed to 0.22, roughly half its 20-day average of 0.46…
Snapshot as of 29 Sept 2026
TRAX — First Tracks Biotherapeutics — has shed nearly 9% in a week despite one of the most bullish analyst postures of any small-cap biotech on Nasdaq, making the gap between Street conviction and price action the…
First Tracks Biotherapeutics arrives at its August 14 earnings event with the short side in clear retreat and the analyst community converging on the upside — a combination that sets a high bar for the print. Short…
TRAX heads into its August 13 earnings report on the back of a 32% surge over the past month — a move driven by clinical newsflow but now demanding validation from the numbers. The analyst community has responded to…
First Tracks Biotherapeutics enters the second week of July with an interesting split: the Street is firmly in the bull camp, yet the stock has given back ground after a strong month, and institutional ownership tells…
First Tracks Biotherapeutics enters the week of May 11 with a stark contradiction at its centre: six Wall Street firms initiated coverage in the past month with unanimous bullish ratings, yet the stock has shed 31%…
TRAX — First Tracks Biotherapeutics — enters the weekend carrying two stories in direct tension: one of the more aggressive analyst coverage launches seen for a small-cap biotech, and a Friday-evening resale prospectus…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TRAX — free to start on ORTEX.
Sign up for free →Open TRAX on ORTEX